APIXABAN 

The second factor Xa (after rivaroxaban) to be approved in the United States is apixaban (Eliquis; Bristol-Myers Squibb/ Pfizer).  The clinical trials with apixaban have revealed less renal excretion than with dabigatran or rivaroxaban; unlike warfarin it has no food interactions, but as with the other factor Xa inhibitors, apixaban has P-glycoprotein and CYP3A4 interactions. Unlike rivaroxaban, however, apixaban requires twice-daily (bid) dosing. 

As shown in the Figure, the 2 pivotal trials with this drug have been AVERROES[97] and ARISTOTLE.[98] In AVERROES, apixaban was clearly superior to aspirin; however since current guidelines already mandate that antiplatelet therapy is insufficient in patients with a CHA₂DS₂-Vasc score ≥1, those results are not important for this presentation.  ARISTOTLE was a comparison of apixaban versus warfarin, which is important because that allows indirect comparison with ROCKET AF trial (with rivaroxaban)^[[97] and the RE-LY trial (with dabigatran).[96]

Reiffel JA. Am J Med 2013; 126: 00-00.